Protara Therapeutics with ticker code (TARA) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 50 and 37 calculating the average target price we see 45.67. With the stocks previous close at 24.68 this is indicating there is a potential upside of 85.0%. There is a 50 day moving average of 22.35 and the 200 day MA is 23.42. The market capitalisation for the company is $258m. Find out more information at: http://www.protaratx.com
The potential market cap would be $477m based on the market concensus.
Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics and changed its name to Protara Therapeutics in May 2020. Protara Therapeutics is based in New York, New York.
